BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sekimoto T, Maruyama H, Kiyono S, Kondo T, Shimada T, Ishibashi H, Takahashi M, Yokosuka O, Yamaguchi T. Hepatic filling rate of a microbubble agent: a novel predictor of long-term outcomes in patients with cirrhosis. Ultrasound Med Biol 2014;40:2082-8. [PMID: 25018029 DOI: 10.1016/j.ultrasmedbio.2014.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Maruyama H, Kato N. Contrast-Enhanced Ultrasonography for the Diagnosis of Portal Hypertension. Diagnostic Methods for Cirrhosis and Portal Hypertension 2018. [DOI: 10.1007/978-3-319-72628-1_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Joo I, Lee JY, Lee DH, Jeon JH, Kim H, Yi N, Lee K, Suh K. Contrast-Enhanced Ultrasound Using Perfluorobutane-Containing Microbubbles in the Assessment of Liver Allograft Damage: An Exploratory Prospective Study. Ultrasound in Medicine & Biology 2017;43:621-8. [DOI: 10.1016/j.ultrasmedbio.2016.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Maruyama H, Shiha G, Yokosuka O, Kumar A, Sharma BC, Ibrahim A, Saraswat V, Lesmana CR, Omata M. Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography. Hepatol Int. 2016;10:267-276. [PMID: 26696585 DOI: 10.1007/s12072-015-9670-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
4 Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015;9:603-27. [DOI: 10.1586/17474124.2015.1007955] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 11.4] [Reference Citation Analysis]